In this episode of the HAYVN Hubcast, Nancy Sheed welcomes back Katherine Saunders, co-founder of FlyteHealth, for a powerful conversation on the evolution of obesity and cardiometabolic care.Since her last appearance—when her company was still in its early stages under the name IntelliHealth—Katherine has led a transformation from a software-focused startup into a comprehensive virtual clinical care provider. Now rebranded as FlyteHealth, the company delivers integrated cardio-kidney-metabolic care directly to patients, while partnering with employers to reduce healthcare costs and improve outcomes.Katherine explains how the rise of GLP-1 medications like Wegovy, Ozempic, and Zepbound changed the national conversation around obesity. But she cautions against the current “GLP-1-only” mindset, emphasizing that true success requires comprehensive medical evaluation, personalized treatment plans, and ongoing support—not just a prescription.The discussion explores: Why obesity medicine was historically overlooked in medical training How GLP-1 demand has reshaped employer healthcare strategies The financial strain these medications place on self-insured employers Why fragmented healthcare leaves patients overwhelmed The importance of care navigation and communication between specialists How technology can enhance—not replace—the provider-patient relationshipFlyteHealth’s model blends advanced clinical decision support tools with human-centered care, allowing providers to practice at the top of their training while delivering better outcomes for patients and better ROI for employers.Key Highlights From Software to Full-Service Clinical CareFlyteHealth began as a tech platform to scale obesity treatment but evolved into a direct care provider when it became clear that technology alone wasn’t enough. The GLP-1 Explosion — and Its LimitsWhile GLP-1 medications have revolutionized obesity treatment, Katherine stresses that medication without comprehensive care leads to poor outcomes and rising costs. The Employer Healthcare DilemmaSelf-insured employers face skyrocketing costs for GLP-1 medications. FlyteHealth offers a structured, outcomes-focused program that balances access with cost control. Obesity as a Root DiseaseTreating obesity improves or prevents over 200 related conditions, including hypertension, prediabetes, and cholesterol issues—making integrated care essential. Technology as a Support System, Not a SubstituteClinical decision support tools gather and analyze data before visits, allowing providers to spend more time educating and connecting with patients.This conversation highlights a pivotal moment in healthcare. The excitement around GLP-1 medications has brought long-overdue attention to obesity as a serious medical condition—but as Katherine makes clear, prescriptions alone are not the solution. Sustainable results require comprehensive care, personalized treatment, coordinated communication, and smart use of technology.FlyteHealth represents a model for where healthcare is heading: integrated, data-informed, and human-centered. As employer-sponsored healthcare continues to evolve and new therapies enter the market, thoughtful systems like this may be what keeps care both effective and financially sustainable.Connect with NancyLinkedIn InstagramWebsiteConnect with KatherineLinkedInWebsiteLearn more about your ad choices. Visit megaphone.fm/adchoices